Evobrutinib

Evobrutinib
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one;
CAS Number	1415823-73-2;
PubChem CID	71479709;
DrugBank	DB15170;
ChemSpider	58827807;
UNII	ZA45457L1K;
KEGG	D12467;
ChEMBL	ChEMBL4072833;
Chemical and physical data
Formula	C25H27N5O2
Molar mass	429.524 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N;
	InChI InChI=InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29); Key:QUIWHXQETADMGN-UHFFFAOYSA-N;

Evobrutinib is an experimental drug being studied for the treatment of encephalomyelitis and multiple sclerosis.^[1]^[2]^[3] It is an inhibitor of Bruton's tyrosine kinase.^[4]

References

^ "Evobrutinib". AdisInsight. Springer Nature Switzerland AG.
^ Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, et al. (April 2024). "Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study". Multiple Sclerosis. 30 (4–5): 558–570. doi:10.1177/13524585241234783. PMC 11080380. PMID 38436271.
^ Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BA, Cross AH, et al. (November 2024). "Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials". The Lancet. Neurology. 23 (11): 1119–1132. doi:10.1016/S1474-4422(24)00328-4. PMID 39307151.
^ "Evobrutinib". Multiple Sclerosis Trust.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.